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The field of mechanical circulatory support is evolving rapidly and new data are
published at a rate that can be overwhelming. In this review, we summarized
some of the publications from 2014 that we think are particularly important. We
have also included a few selected papers from the end of 2013 and the very
beginning of 2015. Some of this overlap reflects the inevitable delay between
online and paper publications.
Readers who wish to supplement this review or argue with the author’s
statements are encouraged to do so on our Facebook page at
https://www.facebook.com/TheVADJournal.

Outcomes
The sixth annual report of the Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) presented data for 10,000 patients on long
term ventricular assist devices (VADs). Actuarial survival on continuous-flow
pumps is 80% at 1 year and 70% at 2 years. A total of 141 centers are approved
for destination therapy implants (1).
McIlvennan et al. (2) reviewed the data systematically and summarized the data
from clinical trials and registries that relate to outcomes on continuous flow
LVADs (Figure 1).
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Fig 1. Estimated Actuarial Survival of continuous flow LVAD; reproduced
from McIlvennan et al. (2), with permission
Interestingly, mortality in LVAD patients is improving but morbidity remains
approximately the same. Khazanie et al. (3) analyzed outcomes between 2006
and 2011 for patients who received LVADs and who were Medicare
beneficiaries. They concluded that short and long term mortality decreased while
the admission rate remained stable at about 80%. Unlike mortality, admission
rate did not depend on the number of implants performed by the center. We look
forward to seeing the data from 2011 onwards as we predict that morbidity will
drop as centers gain experience in post-LVAD care.
Good outcomes with LVAD implantation in uninsured patients in the USA were
reported by Rajagopalan et al.(4). This study analyzed patients from our
institution. Almost all of them benefited from a device.
Outcomes for specific devices were also reported in 2014. Data from the postmarket Registry to Evaluate the HeartWare Left Ventricular Assist System
(ReVOLVE) confirmed excellent outcomes in 254 commercial implants with a
mean duration of support of 363 ± 280 days (median 299.5 days). The survival
was 87% at 6 months, 85% at 1 year, 79% at 2 years and 73% at 3 years (5).
Bernhardt et al. (6) shared European experience with HeartWare (HeartWare
Inc., Framingham, MA) for isolated right ventricular (RV) dysfunction with
preserved left ventricular (LV) function. There were a total of 8 such patients in
the EUROMACS registry, all with acute RV failure due to acute myocardial
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infarction, failure to wean from cardiopulmonary bypass, or post-cardiotomy
syndrome. Although only 3 patients survived to either heart transplant or
recovery, most programs lack experience with these types of patients, so the
data are very valuable.
Short term hemodynamic support
To our knowledge, Stretch et al. (7) presented the first data quantifying the
impact on outcomes of short-term hemodynamic support. In adult patients, who
received receiving short-term mechanical circulatory support (MCS) in the United
States from 2004 to 2011, use of percutaneous devices (Tandem-Heart and
Impella) for short-term MCS increased by 1,511% compared with a 101%
increase in non-percutaneous devices (Centrimag and some older devices).
Intra-aortic balloon pump and ECMO were excluded from the analyses. The most
rapid growth started in 2008. Mortality rates in patients on short-term support
declined from 41.1% in 2004 to 2007 to 33.4% in 2008 to 2011 (p for trend =
0.027). Mortality in cardiogenic shock decreased from 51.6% to 43.1% (p for
trend = 0.012). Hospital costs also declined (p for trend = 0.011).

Candidate Selection
Several papers in 2014 focused on candidate selection and presented valuable
data relating to indications and contraindications/precautions.
RV failure
An analysis of INTERMACS data showed that more than 70% of patients with
chemotherapy (anthracycline) induced cardiomyopathy are female. These
individuals required more right ventricular assist device support than patients with
non-ischemic and ischemic cardiomyopathy (19% vs.11% versus 6%, p=0.006)
(8).
Obesity
An article by Chaudhry et al. (9) showed that LVADs can be implanted in very
obese patients, who can subsequently undergo a weight reduction surgery. Six
morbidly obese patients (body mass index 47.6 ± 3.0 kg m-2), half of them
already on LVAD support, underwent laparoscopic sleeve gastrectomy. One of
the three LVAD patients developed pump thrombosis and required pump
exchange. Surgery in the other two patients was uneventful. At median follow-up
of 22 months, mean body mass index decreased to 34.3 ± 2.4 kg m-2. All six
patients became transplant candidates.
Frailty
Handgrip strength was reported as an easy to measure variable that predicts
outcomes in patients with LVADs. When measured in 72 patients before and
after LVAD implantation, grip strength increased by 18.2 ± 5.6% at 3 months and
The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.06
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by 45.5 ± 23.9% at 6 months. Patients with a handgrip strength <25% of body
weight had an increased risk of mortality and increased postoperative
complications (10). Frailty before destination LVAD implantation was also
associated with increased risk of death (11).
Adult congenital disease
One of the most challenging tasks in cardiology is caring for adults with single
ventricle physiology. Failure of the systemic morphologic right ventricle is
frequently encountered in congenitally corrected transposition of the great
arteries or after atrial switch for transposition of the great arteries. Peng et al.
(12) reported their experience with 7 such patients (mean age 36 years) who
received HeartWare devices.
There were no early deaths within 30 days. The rate of stroke was high at 43%
(hemorrhagic and ischemic combined). Overall, 6 of the 7 patients (86%)
returned home. More specifically, 3 patients (44%) received a cardiac transplant,
2 patients (28%) died of non-cardiac causes, and the remaining 2 individuals
(28%) continued on VAD support for a median length of 232 days. The three
patients that received transplants showed an improvement in median
transpulmonary gradient (18.5 mm Hg to 8.0 mm Hg) in repeat catheterizations.
The authors conclude that LVAD is a reasonable strategy for such patients.
New data from experiments with pigs may also help to advance the treatment of
congenital heart defects. A porcine model of Fontan physiology was created by
surgically placing catheters from the inferior and superior cava veins to the
pulmonary artery. A VAD was then implanted into the common graft to facilitate
pulmonary circulation. Arterial pressure and aortic flow, which both decreased
dramatically with Fontan physiology, returned to baseline after the VAD implant.
Similarly favorable changes occurred within the systemic venous circulation (13).
This raises the hope of using VADs as a bridge to transplant in failing Fontans.

LVADs and Co-Morbid Conditions
Arrhythmias
There are still no clear results showing how to manage arrhythmia in patients
with LVADs.
Atrial arrhythmia
A particularly interesting study was published by Sean Pinney’s group from
Mount Sinai, New York. In retrospective review, paroxysmal or persistent atrial
fibrillation was present in 51.9% of patients. While paroxysmal atrial fibrillation did
not adversely affect outcomes, the persistent form of fibrillation was associated
with an increased composite endpoint of death or HF hospitalization (HR: 3.54;
95% CI 1.52 to 8.25; p < 0.01). The difference was mainly driven by HF
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hospitalizations. These patients also had thromboembolic events at higher
international normalized ratios (INRs) (14). .
Brisco et al.(15) also showed that atrial arrhythmias in HeartMateII trials were
associated with lower quality of life and slower functional recovery but did not
influence mortality. Unfortunately, the authors did not define atrial arrhythmias in
their report and, moreover, analyzed supraventricular arrhythmias separately. We
presume that the majority of the patients had atrial fibrillation but there may be
alternative explanations.
Ventricular arrhythmia
It is well known that ventricular tachycardia/fibrillation is generally well tolerated
in patients with LVADs. To underscore this, a case report published by Naito et
al.(16), describes a patient who was supported by an LVAD through incessant
ventricular fibrillation, resistant to all anti-arrhythmics, for 18 months.
On the other hand, a study from the Cleveland Clinic demonstrated that cardiac
output in patients on LVAD support drops by about 30% during ventricular
fibrillation. These tests were performed in the electrophysiology laboratory during
defibrillation threshold testing. Cardiac output returns to baseline seconds after
successful defibrillation (17). This finding explains why many LVAD patients are
symptomatic during ventricular arrhythmias even though they don’t die.
Ablation for ventricular tachycardia remains a topic of interest. Garan et al. (18)
reported successful ablation of ventricular tachycardia in 6 out of 7 patients with
LVADs. In almost half of the patients, the source of tachycardia was located in
the apex.
Cardiac resynchronization devices, when compared to implantable defibrillators,
did not significantly improve mortality, all-cause hospitalization, LV dimensions,
or incidence of arrhythmias in LVAD recipients (19).
LVAD and diabetes
Several reports in 2014 confirmed Uriel et al.’s 2011 discovery (20) that diabetes
improves after LVAD. Our own group reported that HbA1C, which was 7.6 ± 1.6
% before LVAD, decreased to 5.7 ± 0.9 % within 3 months of the implant and
remained below the pre-LVAD level for at least 12 months. (21). Choudhary et
al.(22) also found that fasting blood glucose improved from 136 ± 35 to 108 ± 29
mg dl-1 post-LVAD (p < 0.001), and daily insulin dose decreased from 43 ± 37 to
29 ± 24 units (p = 0.02). Mohamedali et al.(23) presented similar findings and
added that some patients were able to completely discontinue oral
hypoglycemics. Subauste et al. also published related data (24).
The mechanisms underlying this phenomenon remain unclear. Koerner et al.
measured cortisol and plasma catecholamine levels and found that both
decreased after the LVAD implant. (25). This may implicate systemic
inflammatory and stress responses. Another possibility is that improved
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hemodynamics in the pancreas and/or peripheral tissues increase glucose
metabolism. Irrespective of the mechanism, diabetes should not be considered a
contraindication to LVAD.
LVAD and valves
An excellent review of valvular problems in LVAD patients was published by the
group from Duke (26). The summary table is reproduced below (Figure 2).

Fig 2. Approach to valvular problems in LVADs; reproduced from Wang et
al. (26), with permission
Detailed analysis of the clinical data for 382 patients supported by HeartWare
devices in the ADVANCE trial demonstrated that concurrent valve surgery during
the device implantation resulted in higher postoperative early RV failure but
similar one year survival compared with implantation only (27). Valve surgeries
were performed in ~20% of patients (56 tricuspid, 13 aortic, and 6 mitral valve
procedures). Unoperated severe tricuspid regurgitation was associated with
higher odds of late postoperative RV failure.
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Analysis of the much larger cohort of 1106 patients who received HeartMate II
devices in clinical trials showed similar results. About 20% of patients had
concomitant valve procedures and their survival was impacted.
Patients undergoing both LVAD implantation and valvular surgery were older,
had higher blood urea nitrogen levels, higher central venous pressure, and
decreased right ventricular stroke work index. Their 30-day mortality was higher
(10.3% versus 4.8% for LVAD alone, P = 0.005). These patients also had higher
rates of right heart failure and received more right ventricular assist devices (28).
Tricuspid valve
Extra caution may be appropriate when considering concomitant tricuspid valve
repair in tricuspid regurgitation. Robertson et al. (29) analyzed the outcomes for
588 patients from 115 institutions who had moderate to severe tricuspid
regurgitation and who underwent tricuspid valve repair when they received their
LVAD. The most common procedure was annuloplasty. The authors concluded
that tricuspid valve repair was associated with an increased risk of post-operative
renal failure, dialysis, reoperation, greater transfusion requirement, longer times
on a ventilator and in the intensive care unit, and longer hospital stay. There was
no effect on operative mortality or post-operative RVAD requirement. Long term
outcomes were not reported in this paper.
On the other hand, some single center studies, such as the one from Henry Ford
Hospital, Detroit, MI, saw survival benefit in concomitant tricuspid valve repair
(30).
Aortic valve
The Columbia university program summarized their experience with aortic
regurgitation in 232 LVAD patients. They repaired the aortic valve in 43 of these
individuals at the time of implant. After three years on support, about 40% of
patients developed at least moderate aortic regurgitation. This was particularly
common if the aortic valve remained closed during LVAD support. Seven of the
patients with moderate or severe aortic insufficiency developed symptoms of
heart failure, requiring surgical intervention (31).
Interestingly, British investigators found that the incidence of aortic regurgitation
was lower in HeartMate II than in HeartWare recipients (43.1% versus 65.7%, p
=0.035) (32). Overall, de novo aortic regurgitation after LVAD implant did not
affect survival (33).
For the first time, based on the INTERMACS data, it was shown that closure of
aortic valve during LVAD implant compromises survival (34).
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Innovative approaches to valvular problems, published in 2014, include
transcutaneous aortic valve replacement for severe aortic regurgitation (35), and
transcutaneous aortic valve replacement via left ventricular assist device inflow
cannula (36).
Resuscitation in LVADs
In a small case series, chest compressions during cardiac arrest in 8 LVAD
patients did not result in dislodgement of the cannulae or other device
complications (37).
Another group of authors searched existing literature and fond 10 other cases of
chest compression (longest duration of chest compression was 150 minutes),
also without complications. In some cases, neurological function was regained.
However, assessment of the efficacy of the compressions was not the objective
of either study (38).

Complications of the VADs
Pump thrombosis
Pump thrombosis was, perhaps, the leading topic of the year, with many
excellent papers. The discussion was launched in late 2013 when the New
England Journal of Medicine published the paper by Starling et al. (39) reporting
abrupt growth in pump thrombosis (2.2% to 8.4%) between 2011 and 2013. This
was observed at the Cleveland Clinic, Duke, and Barnes-Jewish. At the same
time, the time from implant to pump thrombosis shortened from 18.6 to 2.7
months. This increase was also apparent in an analysis of data from
INTERMACS (40).
Data suggest that increased lactate dehydrogenase (>600 U/mL for HeartMate II
and >400 U/mL for Heartware) is the most reliable predictor of pump thrombosis
(41), and some centers have adopted the policy of immediate hospitalization
based on elevated LDH alone. The best way to treat patients who have elevated
LDH but no clinical signs of pump thrombosis is still unclear.
An echocardiographic method of the diagnosis of pump thrombosis was
proposed by Estep et al. (42). These authors leveraged the principle that in a
normally functioning LVAD, higher pump speed results in reduced LV
dimensions, less opening of the aortic valve, and longer filling times (longer mitral
E wave deceleration time). Specifically, the authors measured LV end diastolic
dimension, aortic valve opening duration, and E wave deceleration time as they
increased the revolutions per minute (rpm) from 8000 to 12000 in HeartMate II
devices (2 minutes per stage, 1000 rpm increments). Thrombosis was indicated if
patients had a less than a 0.6 cm reduction in LV end-diastolic dimension, less
than an 86 ms shortening of aortic valve opening, and less than a 73 ms increase
mitral E wave deceleration time. Matching one of these criteria predicted pump
malfunction (normally due to thrombosis) with 100% sensitivity and 89%
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specificity. Matching two parameters increased these values to 100% sensitivity
and 95% specificity.
A very innovative method of detecting pump thrombosis was proposed by the
Berlin group. They recorded the sound produced by HeartWare devices and
noticed that the acoustic spectrum was different if the pump contained a
thrombus. Eight pumps were exchanged because of their acoustic signature and
thrombi were confirmed in each case (43).
In terms of treatment of pump thrombosis, eptifibatide, once again, appeared to
cause more harm than good, with many bleeding events and very modest
therapeutic benefits reported (44). A case series with bivalirudin also reported
high recurrency rate, with most patients eventually receiving a transplant or pump
exchange (45). There was an anecdotal report of good experience with
argatroban (46).
Complications were reported when investigators tried to facilitate intermittent
opening of the aortic valve by decreasing the LVAD speed. Such practice
increased the rate of thromboembolic events (47). This may be because high
flow rates dissipate heat from the LVAD more effectively than low flow conditions.
Karimi et al.(48) tested using thrombelastography to adjust antiplatelet therapy in
57 HeartMate II recipients. These patients were followed for about a year.
Specifically, the authors adjusted aspirin and dipyridamole to maintain maximum
amplitude (a measure of clot strength) between 60 and 70 mm. This allowed
aspirin and dipyridamole to be used in lower doses in some patients. The rate of
bleeding events was 0.21 per patient-year, which was lower than historic controls
collected from the literature. Specifically, in 7 other studies where no tests were
used to adjustment of antiplatelet therapy, the rate of bleeding events was 0.49
events per patient-year.
Gastrointestinal bleeding
Much attention was paid in 2014 to the nature of acquired von Willebrand
syndrome. It is now widely accepted that the sheer stress produced by a
continuous flow pump destroys multimers of von Willebrand factor. The larger
multimers capture more platelets and facilitate their adhesion and aggregation.
The destruction of the multimers impairs hemostasis and causes bleeding. This
year, several papers elucidated on the role of metalloprotease ADAMTS-13,
which apparently plays an important role in destruction of this coagulation factor.
In particular, Bartoli et al. (49) used a laboratory vortexer to mimic the effects of
an LVAD on von Willebrand factor. Their control experiments showed that the
vortexer modestly reduced the concentration of large von Willebrand factor
multimers. Adding ADAMTS-13, the von Willebrand factor protease, substantially
enhanced the degradation of the large multimers and also increased the
concentration of degradation fragments. These effects are similar to those
induced by LVADs. Bartoli et al. concluded that sheer stress alone is not enough
The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.06
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to destroy the von Willebrand factor. They also suggested that targeting
ADAMTS-13 may preserve the multimers, prevent their cleavage into fragments,
and reduce gastrointestinal (GI) bleeding in patients with LVADs.
One potential strategy described by Bartoli et al. is to use tetracycline antibiotics.
These drugs inhibit matrix metalloproteinases (such as the ADAMTS protease)
and might therefore impact von Willebrand factor degradation. Doxycycline is an
example of a tetracycline antibiotic that has been used safely for years (for
example, for acne) and that could be tested relatively easily in patients who have
LVADs. As an additional benefit, tetracyclin might help to prevent driveline
infections caused by methicillin-resistant Staphylococcus aureus.
Additional manuscripts presented anecdotal evidence that GI bleeding could be
controlled with the following medications:
•

Danazol (200 mg BID) (50)

•

Octreotide (100 mcg SC BID in the hospital and then 20 mg depot
IM monthly) (51). Other authors report 50 mcg SQ BID (52).

•

Thalidamide (50 mg BID with potential increase to maximum daily
dose of 200 mg, reduce to 50 mg QOD if toxicity develops),
monitor blood count while up-titrating, try decreasing the dose
when therapeutic effect achieved (53,54).

Additional strategies described in 2014 include double balloon enteroscopy. This
was reported to provide a high diagnostic yield of 69%, and an even more
impressive therapeutic effect of 89 %. These results were achieved using argon
plasma coagulation, epinephrine injection, and/or hemoclip placement (55).
Hirose et al. (56) suggested initiating work-up for GI bleeding with deep bowel
enteroscopy and omitting the usual upper and lower endoscopy and capsule
endoscopy because they are low-yield procedures. This approach appeared to
reduce the number of procedures and transfusions and also to reduce costs.
Unfortunately, not every hospital has the equipment for deep bowel enteroscopy.
Several papers reported that anticoagulation in LVAD patients can be safely
reversed. Data from the Henry Ford Hospital program described 38 reversals of
anticoagulation in 25 patients using vitamin K at a mean dose of 10 ± 8 mg or
fresh frozen plasma. Only one patient had a thromboembolic event within 30
days of reversal (57).
14 of 213 (6.5%) patients at the University of Minnesota had discontinuation of
anticoagulation: 10 patients had warfarin discontinued and 4 had both aspirin and
warfarin discontinued. Most of these interventions were for GI bleeding. The
mean duration off warfarin was 392 days. There was only one pump thrombosis
episode, and this occurred in the patient with surgical malpositioning of the LVAD
cannula (58).
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Infections in LVADs
Several excellent papers were published in 2014 relating to infections. The
importance of burying the velour portion of the HeartMate II driveline well under
the skin was underscored by Singh et al (59). This technique improved driveline
infection-free survival. 44.4% of patients had driveline infections when velour was
exposed but the infection rate was only 8.8% when the exposed region was
silicone.
Yarboro et al. (60) shared experience from the University of Virginia where the
driveline infection rate dropped from 20% to zero. They described, step by step,
their approach to driveline care at every stage of LVAD implantation and followup.
Kretlow et al.(61) reported the use of antibiotic beads for salvage of LVADs with
deep infection in the pocket. 17 of 26 patients with LVAD-related infections were
cleared of their infection and many survived. Plastic surgery was often required
to cover the device with a flap.
A strong association between LVADs and blood stream infection was described
by Trachtenberg et al.(62). Out of 149 patients who received an HMII device, 19
patients (13%) had strokes (7 hemorrhagic and 12 ischemic). During the same
period, there were 28 patients (19%) with persistently positive blood cultures and
17 patients (11%) with intermittently positive blood cultures. Only persistently
positive blood cultures were associated with an increased risk of mortality and
with all cause cerebrovascular accident on multivariate analysis (OR 5.97,
P=0.003).

Recovery
Diakos et al. (63) discovered, that, unlike animal models, human hearts do not
develop cardiomyocyte atrophy as a result of prolonged mechanical circulatory
support. Cardiomyocyte size (cross-sectional area) decreased after LVAD
unloading but not beyond that of normal donor hearts. Other approaches that did
not show evidence of myocardial atrophy included evaluation of ultrastructure
using electron microscopy, analysis of cardiomyocyte glycogen content, and
echocardiographic assessment of myocardial mass and left ventricular function.
We note that patients were only followed for 6 months in this study and, in our
opinion, atrophy could still occur after longer period of support.
Some genetic predisposition to myocardial recovery while on LVAD support was
demonstrated by Posch et al.(64). They studied a connective tissue growth
factor that is associated with adaptive cardiomyocyte hypertrophy.
Homozygosity of the promoter-activating G allele was overrepresented in
patients with cardiac recovery (50%) relative to patients who did not recover
(17%).

The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.06

Page 11 of 23

The VAD Journal: The journal of mechanical assisted circulation and heart failure
	
  
	
  
	
  

Non-Cardiac Surgery
An interesting survey of current practices was published by Sheu et al. (65). 72%
of inpatient endoscopic procedures were performed in the endoscopy suite. Most
(59%) procedures were also completed by a solo practitioner with a 1:1 staffing
ratio. LVAD coordinators were present for more than 80% of all procedures. Both
endoscopy and surgical patients used recovery units and intensive care units for
recovery. Patients who had non-cardiac surgery recovered in the intensive care
beds more often than those who had endoscopy (45.5% versus 29.1%, p <
0.001). 18% of endoscopy patients recovered on site. An arterial line for blood
pressure monitoring was inserted in ~50% of the endoscopy patients and in 71%
of surgical patients. Institutions with high LVAD volumes used less invasive
monitoring.

Imaging in LVADs
Two papers that focus on echocardiographic evaluation of LVAD patients and
which we judge to be particularly important were published by Jerry Estep and
co-authors. One of the manuscripts discussed using echocardiography to
diagnose pump thrombosis (42) and was discussed earlier in this article.
The second article compared invasive and echocardiographic hemodynamic data
and found that hemodynamic echo measurements are valid in patients supported
by continuous flow LVADs. Good correlations were obtained between invasively
measured and non-invasively estimated values for mean right atrial pressure (r =
0.863; p < 0.0001), systolic pulmonary artery pressure (r = 0.880; p < 0.0001),
right ventricular outflow tract stroke volume (r = 0.660; p < 0.0001), and
pulmonary vascular resistance (r = 0.643; p = 0.001). Furthermore, the authors
proposed an algorithm that was able to distinguish between patients with normal
and elevated left ventricular end diastolic pressure with 90% accuracy (Figure 3)
(66).
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Fig 3. Echocardiography algorithm for estimation of left ventricular filling
pressure in LVAD patients; reproduced from Estep et al. (66), with
permission
A comprehensive review of echocardiographic assessment of patients who are
being considered for LVAD treatment as well as patients who are already on
LVAD support was published by Todaro et al (67). We found the following
algorithm of assessment of the right ventricle prior to implant very helpful (Figure
4).
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Fig 4. Echocardiographic assessment of the right ventricle before LVAD
implantation; reproduced from Todaro et al. (67), with permission
Finally, a nice series of images showing how PET/CT can be used to find the
exact location and the extent of LVAD-related infections was published by Kim et
al (68).

New Pumps
Several interesting new pumps were introduced or developed further in 2014.
A HeartWare MVAD
A HeartWare MVAD (HeartWare, Miami Lakes, FL) pump (length 50mm,
diameter 21 mm; maximum flow 7–8 liters/min) was combined with a novel inflow
cannula and tested in sheep with good results (69) (Figure 5).
Impella for RV support
In January of 2015, the FDA approved a percutaneous right-sided Impella PR
(right peripheral; Abiomed, Danvers, MA) for 14 days of support for right
ventricular failure under a humanitarian device exemption (Figure 6). The
approval was based on the results of the RECOVER-RIGHT study which is still,
to the best of our knowledge, unpublished. According to clinicaltrials.gov, the
goal of this study is to show that using the Impella RP is safe and feasible and
that the device provides a hemodynamic benefit in patients with right ventricular
failure (https://clinicaltrials.gov/ct2/show/record/NCT01777607).
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Fig 5. Miniaturized HeartWare LVAD; reproduced from Schima et al. (69),
with permission
Data from the trial were presented by William O'Neill at the TCT meeting in 2014.
A total of 30 patients were supported with a right-sided Impella, with a 30 day
survival of 73%. Patients who developed right ventricular failure after receiving
an LVAD had a mean survival of 83.3% while patients with right ventricular failure
due to acute myocardial infarction or postcardiotomy syndrome had a mean
survival
of
58.3%
(Abiomed
press
release
at
http://investors.abiomed.com/releasedetail.cfm?ReleaseID=871213).
Additional positive data were published by Cheung et al.(70) from Vancouver,
British Columbia, Canada. They presented a retrospective analysis of 18
patients. All of these individuals were on intravenous inotropes, 39% on inhaled
nitric oxide, 39% on intra-aortic balloon counterpulsation, and 11% survived
cardiac arrest. Device implantation increased the mean cardiac index from 2.1 to
2.6 L min-1 m-2 (p=0.04) and reduced central venous pressure from 22 to 15 mm
Hg (p < 0.01). 14 of the 18 patients had their Impella device explanted due to
recovery. The other 4 patients died on support. Survival to 30 days was 72% and
to 1 year was 50%.
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Neither of the above studies compared outcomes with Impella support to
outcomes without an Impella.

Fig 6. Impella RP (right peripheral); reproduced from Cheung et al. (70),
with permission
The Synergy CircuLite for partial support
The Synergy Micro-pump (HeartWare Inc, Framingham, MA) is the smallest
implantable LVAD that is currently available and can produce flows of up to 4.25
L min-1. This device was tested in 7 INTERMACS class 1–2 patients and 6
INTERMACS class 3–4 patients. The mean support times for the two groups
were 108 ± 114 days and 238 ± 198 days respectively. The overall survival was
comparable for the two groups, with one late death in each group, log-rank p =
0.608). Two patients from the high-risk group were upgraded to a full-support
LVAD after 65 ± 85 days of support with the Synergy Micro-pump. The authors
concluded that the pump is a feasible approach even in very high risk patients
(71).
Mohite et al. (72) described an algorithm to check for pump thrombosis.
Apparently, the Synergy speed fluctuates periodically at 10-second intervals to
reduce the probability of thrombosis. If the pulse oximeter waveform was
recorded from the index fingers of the left and right hand, patients with normal
device function had a more pronounced variation (giant wave) in the trace from
the right hand than from the left. These giant waves coincided with the variation
in sound detected by auscultation using a stethoscope positioned over the right
infra-clavicular pocket.
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